Replay available

Athenex (ATNX) Q4 2020 Earnings Call

Athenex (ATNX) Q4 2020 earnings call, held 2021-03-01. Watch the replay and read the transcript on 6ix.

Mon, March 1, 2021 at 8:00 AMendedReplay
Athenex (ATNX) Q4 2020 Earnings Call
Company
Athenex Inc
Period
Q4 2020 earnings call
Date
Mon, Mar 1, 2021, 8:00 AM ET
Replay
Watch the replay on this page · 1 h 5 min

On 6ix: 6ix.com/event/athenex-inc-atnx-q4-2020-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Greetings and welcome to the Athenix, Inc. fourth quarter and fiscal year 2020 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Steve Rubis, Senior Director of Investor Relations for Athenix. Thank you. You may begin.

0:31 Good morning and thank you for joining our conference call. This morning we published two press releases. The first announces that we received a complete response letter from the FDA for oral Paclitaxel. The second announces our fourth quarter and full year 2020 financial results. These news releases crossed the wire earlier this morning and are available on our website. Today we will provide an update on Athenix's business as well as a review of financial results for the fourth quarter and full year 2020. A replay of this call will also be archived on the company website. During the conference call, the company will make projections or forward-looking statements regarding future events, including statements about financial, business, and clinical milestones anticipated in fiscal year 2021 and beyond.

1:21 We encourage you to review the company's past and future filings with the SEC, which identify specific factors that may cause the actual results or events to differ materially from those described in the forward-looking statements. You can find our SEC filings in the EDGAR database at www.sec.gov or in the investor relations section at our website at www.athenex.com. This morning, we are joined by Dr. Johnson Lau, Chief Executive Officer, Mr. Jeff Yorden, Chief Operating Officer, Dr. Rudolph Kwan, Chief Medical Officer, and Mr. Randall See, Chief Financial Officer, who all will be available to answer questions after the prepared remarks. I will now turn the call over to Johnson for introductory comments.

2:13 Thank you, Steve. I will provide an update regarding the complete response letter we received for Oropacatexel and our first FDA-approved product, Casiri, and its launch before turning the call over to our chief medical officer, Dr. Rudolph Kwan. This morning, we announced that the FDA issued a complete response letter related to the new drug application for Oropacatexel. We are surprised and disappointed with the FDA's decision. We believe that autopracketexel demonstrated a superior efficacy and safety profile in a well-controlled phase three trial setting, and we remain committed to exploring all options to unlock value from this asset.

3:05 I will give a quick recap of the issues raised in the complete response letter, and Dr. Kwan will provide additional details later in the call. The FDA expressed concerns about safety risks associated with the increase in neutropenia-related sequelae. The agency also expressed uncertainty with regard to the primary endpoint assessment conducted by the Blinded Independent Central Review in the Phase III trial. The FDA recommends We submit results from the new clinical trial and Dr. Kwan will elaborate on all of these later. The Infinix team is actively working to analyze and respond to the complete response letter.

3:55 We will request a meeting with the FDA to discuss its concerns as soon as possible. During the meeting, we hope to align with the FDA on the path forward required to obtain approval. The complete response letter represents a disappointing outcome, not only for us, but also for our colleagues, clinicians, and patients who helped facilitate development of Oropracatexel in Medecine Breast Cancer. As a company, we are working to identify and undertake the appropriate internal organizational adjustments accordingly. We will be able to communicate more about this adjustment once we gain clarity on the path forward for Olpacatexel from the FDA.

4:49 Despite the disappointing outcome with Olpacatexel, our team achieved regulatory success with the FDA approval for Caceri late last year. Let me provide you with an update. The product has been approved for the treatment of actinic keratosis of the face or scalp and has already been launched in the United States with our partner, Admiral. The launch of Caseri in the United States provides physicians with a compelling new product that can benefit patients. Caseri is a novel, topical first-in-class microtubule inhibitor indicated for the topical treatment of adenine keratosis of the face or scalp.

5:35 In two Phase III clinical trials, Cassini demonstrated both efficacy and a favorable side effect profile. The short treatment protocol is unique, as Cassini requires one steady application for only five days. The Demonstrated Efficacy and Safety Profile positions Kesari as a compelling new treatment option for patients with adenocaritosis, the second most common condition with diabetologists in the United States. In mid-February, the New England Journal of Medicine published the results of our two Phase III trials that serve as the foundation for FDA approval of Kesari. The publication of this data reinforced the innovation and clinical significance of Kisari and further raises the profile and awareness of Kisari as a possible treatment option for physicians.

6:35 In terms of launch, Admiral intends to reinforce its U.S. sales force to support the marketing sales force A marketing authorization application is also currently under review by the European Medicines Agency. Infinex maintains attractive economics around the company's partnership with Emerald. In addition to the $50 million in upfront and additional milestone payments already received, Infinex is eligible to receive up to an additional $65 million in aggregate milestone payments associated with the Ethereum launch and expansion into additional indications.

7:21 Additionally, the company is eligible to receive additional sales milestone payments and is eligible to receive tiered loyalty payments starting at 15% of annual net sales. In conclusion, we had regulatory success for CACIRI. For Olpacatexol, I want to reiterate our belief in the superior efficacy and safety profile of Olpacatexol. In Phoenix, we mainly focused on unlocking maximum value around not only Olpacatexol, but also the broader oil discovery program. We are committed to breast cancer patients and are focused on bringing this issue to the market.

8:08 Rudolph? Thank you, Johnson. This morning, we announced that the FDA issued a complete response letter for oral Placritaxel. The complete response letter states that the agency cannot approve the application in its present form. We are surprised and extremely disappointed with this outcome and are analyzing the details of this complete response letter. The agency expressed two main concerns. The first concern revolved around safety risk associated with an increase in neutropenia-related sequelae.

8:57 It is well-accepted that neutropenia represents a known pharmacological effect of Placatexel, especially in patients with hepatic impairment, which is in the Placatexel label. We believe the FDA is particularly concerned on the early myelotoxicity-related death, despite the overall survival benefit trend that we had reported in the study. The second concern expressed by the FDA revolved around uncertainty over the results of the Primary Endpoint of Objective Response Rate, or ORR, at Week 19, conducted by Blinded Independent Central Review, BICR.

9:51 The agency stated that the BICR reconciliation and reread process may have introduced unmeasured bias and inference on the BICR. Our phase three trials used an industry-recognized gold standard of BICR, which is a completely independent and totally blinded process for the primary endpoint of ORR. All procedures were pre-specified and followed. The FDA audited the process within Athenex as a sponsor, the clinical trial site, and imaging lab conducting the BICR, and we were informed that no Form 483s were issued.

10:41 We hope to gain clarity on the BICR concerns when we meet with the FDA. The agency requests that we submit results from a meal-adequate and well-conducted clinical trial in a patient population with metastatic breast cancer representative of the population in the United States. The agency further states that additional risk mitigation strategies to improve toxicity, which may involve dose optimization and or exclusion of patients deemed to be at high risk of toxicity are required to support potential approval of the NDA.

11:29 Throughout the review process, we engaged in a robust dialogue with the FDA regarding our package. As with any FDA review, the agency made information requests and raised questions during the process. We provided a significant amount of information and clinical data to address the agency's questions. During one of these routine exchanges, the company even suggested limiting the population of patients in the label to those without hepatic impairment and would potentially avoid excess early mortality due to myelotoxicity.

12:15 The agency did not accept this proposal. We'll request a meeting as soon as possible to discuss the complete response letter and to align with the FDA on the pathway forward to obtain approval. We continue to have strong conviction in the superior efficacy and safety profile associated with oral brachytexel as demonstrated in our phase three trial. The higher response rate, lower neuropathy, and strong trend in overall survival, coupled with oral delivery, suggests Oroplacatexel could be a meaningful treatment alternative for breast cancer patients.

13:00 We are committed to creating maximum value around not only Oroplacatexel, but also our entire oral discovery program. I'll now turn the call over to Jeff.

13:17 Thank you, Rudolph. I will provide an update on current developments with our infrastructure and supply chain and the existing commercial business. The supply chain for our Polaris III launch is in excellent shape. The Phoenix is responsible for the manufacturing of Polaris III. Our Clarence, New York facility shipped launch quantities to Amaral two weeks ahead of schedule and positioned on well for a successful launch. Furthermore, we are able to supply as much inventory as needed and will far exceed the current forecast.

14:02 The performance of our Clarence facility underscores the high efficiency of our integrated business model. We have recently received approval from the Chinese government to begin manufacturing at our new, larger API facility in Chongqing. The new API facility will allow us to manufacture a portfolio of raw materials and we expect to generate revenues from these products in 2021. Construction of our facility in Dunford, New York is nearly complete The facility will serve the commercial needs of our specialty pharmaceutical business and ultimately those of our proprietary products.

14:53 Beginning in the second half of this year, we plan to dedicate a portion of the facility to manufacturing 503 products. The increased manufacturing capacity will allow us to more than double our capacity for these segments of the business. Currently, we sell every unit we can manufacture, and clearly our goal is to substantially increase our capacity to increase our revenue. Our specially founded business performed well in 2020, and as a result, we recorded 105 sales in product sales, up 31% year-over-year.

15:44 The COVID-19 pandemic drove both positive and negative effects in performance last year. While elective surgeries are down significantly, the demand for specific drugs used to treat COVID-19 hospitalized patients increased. The biggest contributors to sales growth in 2020 included products such as dexmetamidine, azithromycin, piperacillin-tazobactam, and levothyroxine. A Phoenix Pharmaceutical division currently markets 34 products with 63 SKUs, and a Phoenix Pharma solution markets 6 products and 19 SKUs.

16:37 We have just recently launched the room temperature stable cyclophosphamide and we will continue to launch new products in 2021. We have identified over 60 products that we can potentially add to our portfolio, many of which are high margin products. I will now turn the call over to Randall to discuss our financials in more detail.

17:08 Thank you, Jeff. I will highlight a few key financial items in the fourth quarter and for the full year 2020. For more details, please refer to the earnings press release published earlier this morning. Revenues from product sales in the fourth quarter were $21.8 million, a 54% year-over-year increase. For the full year 2020, product sales were $105.3 million, a 31% increase year-over-year. Protocells growth is attributable to significant increase, especially protocells, driven by increased demand for COVID-19-related drugs and the launch of additional products. Protocells growth was partially offset by decreases in API and 503b products.

17:55 On the expense side, SG&A expenses have gone up year over year. Increases in SG&A expenses were primarily due to increasing commercial preparation costs associated with the possible approval of our pocket taxes and workforce expansion at our manufacturing plants. In addition, in the fourth quarter of 2020, we reported a provision for potential credit loss of $8.9 million, which included an outstanding balance due from Shangxia and associated expenses related to currency conversions. The provision is related to the $10 million in license revenue we recognized in the third quarter of 2020 in connection with our partnership with Township.

18:40 Net loss attributable to Inc. for the fourth quarter and the year 2020 were $49.5 million and $146.2 million, respectively, of $0.53 and $0.72 per diluted share, respectively. Excluding the credit loss provision of $8.9 million, net loss attributable to a Phoenix for the quarter was $40.6 million, or $0.43 per diluted share. Excluding the one-time debt extinguishment expenses of $10.3 million and the $8.9 million federal loss provision, net loss attributable to a Phoenix for the full year 2020 was $127 million, or $1.49 per diluted share. As of December 31, 2020, Athenex had cash, cash equivalents, and restricted cash of $36.1 million, and short-term investments of $138.6 million.

19:40 In terms of product sales guidance, we're limiting financial guidance to only the existing product portfolio, which excludes any proprietary products until meaningful sales data from QSERI become available. In 2020, we recorded a significant amount of such revenues for international customers as a result of the global pandemic. However, we do not see these revenues as recurring in nature, and we have been continuing to expand our product portfolio. We currently set our product sales in 2021, excluding any sales from Kisiri to be in line with what we have achieved in 2020. We would like to reiterate our cash runway guidance provided in November.

20:27 Based on our current operating plan, we expect our cash, cash approval, restricted cash, and short-term investments as of December 31, 2020, will get us into the second quarter of 2022. We believe with additional cash preservation measures, our cash runway will get further extended. Please note that our estimates are based on conditions that are known and reasonably noble to us and subject to changes in the business, industry, and macroeconomic conditions. I will now turn the call back to John.

21:03 Thank you, Randall. We will now open the call for questions. Thank you. At this time, we'll be conducting a question-and-answer session. If you'd like to ask a question, please press star 1 on your telephone keyboard. A confirmation tone will indicate your line is in the question queue. You may press Start 2 if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question comes from the line of Uma Rafat with Evercore ISI. Please proceed with your question. Hi, thanks so much for taking our questions. Johnson, as I think about the issues you guys have talked about from the complete response letter, it almost feels like either there could have been exclusionary language for hepatic impairment, or on the response rate side, presumably OS has no bias irrespective of what metrics are used, and it was at least not inferior if not trending in favor.

22:02 So I guess my question is, And we've seen United Therapeutics try this. Why can't you resubmit without any new data? But this time with a lot more resources thrown at it, number one, especially, again, in the context of COVID and some of the challenges with travel for patients. And secondly, if you were to perhaps in parallel start a trial, either single arm or like a keynote 21G, 100 patients, 120 patients, could you have interim data by first half 22? And finally, Johnson, finally, if I may, I'm curious if you guys or FDA did that stringent assessment of response rates and what that looked like. Thank you. Thank you. We'll talk to you. I want to address these clinical questions.

22:53 Uma, thank you for the question. You have quite a number of components on that, so please elaborate. I will repeat some of those if I did not answer all of those, okay? So the question regarding the excluding patients with hepatic impairment, we already made that proposal to the FDA and the FDA did not accept that proposal. Regarding overall survival, as you know, we update overall survival based on around 65% response rate on the presented in the San Antonio in December. We continue to follow up those patients.

23:41 So that is a good point that we will raise with the FDA at the upcoming planned request for meeting as to whether there's any merit in providing a further update when the data becomes even more mature. So can you remind me what other questions I may have missed? I was also just curious if you could run a trial like QNO21G and have interim data by first half 22, which could be used towards filing, and or why can't you just resubmit without new data and more resources going at it?

24:21 I think the first question will depend on what the FDA will provide address will require in their complete response letter. They clearly want a study, so that is a subject for discussion, and we will elaborate on that once we got clarity following the meeting. We certainly will want to go in making a suggestion, so your proposal is not an unreasonable one. We'll take that into consideration. Regarding resubmitting without additional new data, certainly this is a venue we'll discuss at the meeting as well. I would consider perhaps reinforcing the overall survival analysis as I mentioned earlier on, rather than resubmitting without new data.

25:16 That may be more convincing argument, just in my view. Does that answer your question? Thank you very much.

25:26 Just to clarify a bit further for you, Uma, when we were having discussions with our key opinion leaders, some of them actually were highlighting that the overall survival that we measured in our clinical studies will be more effective because there will be not that many other interventional therapies to be applied to the patients. in the geographic areas that we perform our clinical studies. And the comment at that time was that our overall survival analysis should be more clean compared to a lot of the studies conducted in geographic areas that there are a lot more fourth-line, fifth-line therapies that are being tested in terms of creating confusions with regard to analysis. So we felt that that was a very important point and certainly will include all these opinions in our response and presented to the US FDA during our meeting.

26:30 Thank you. Thank you, Uma. Thank you. Our next question comes from the line of Jonathan Chang with SVB Leary. Please proceed with your question. Hi, guys. Thanks for taking my questions. First question, can you provide more color around the regulatory comments suggesting a new study in patients representative of the U.S. population? What specifically is the FDA taking issue with, and what implications does it have in a potential future study? I guess what geographic locations besides the U.S. could this comprise of?

27:11 Yes, thank you for the question. The reference to a US population is very obviously subject to interpretation what they mean, and we certainly would want to clarify that with the FDA. From our perspective, we consider the patient population in terms of receptors of types, the presentation representative of the US population. Whether they have additional concerns about representation of geographic location that none of the centers were done in the U.S., that will be a discussion point. They did not mention the geographic location as a specific issue all along the interaction with the FDA.

28:02 So whether it require the whole study be done in the U.S. or not, we will have to clarify with them in the meeting. Got it. Second question, it seems like the PRL cites multiple issues here. How should we be thinking about the relative weighting of the FDA's concerns over each of these issues? I can't help but wonder if it's in the reverse order of how it's listed in the press release. Any color here would be helpful.

28:35 Thank you. I think it is an interesting observation because each of those two issues on its own are rather Not as clear cut as we would like to hear from the agency. The risk issue of the myelotoxicity, bear in mind myelotoxicity is a known pharmacological effect of Prachetaxel. I relate the fact that hepatic impaired patients are more sensitive is also well-documented in the labeling of IV Placotexil. So those are not surprising things, and clinicians generally can handle it, knowing that it's a pharmacological effect, and having more available, GCSF available, in the humanitarian nowadays. And so certainly it's a surprise to us that they did not accept that by limiting the labeling on the hepatic-impaired patients that would address their concern.

29:53 The other issue of the radiological concern is even more complex. we use industry standard blinded independent central review, which is completely independent, and the readers are totally blinded, and the process are well documented, and it's frustrating for us to hear that they are concerned about the process, especially having witnessed them all of our process, including process in this aspect, having all of the clinical sites conducting the study, and having all of the bioimaging lab that conduct this independent blind process, and still feels that there are unmeasured bias that they cannot articulate clearly. So clearly we have to clarify with the agency what constitute unmeasured bias after all those vigorous inspection of the process and the independency of the REIT. So we will be certainly try to get an explanation from the agency on their view on that during our discussion with them.

31:25 Okay, about the trial, I think the third item, really the third item is the trial, and the trial is, as indicated, will be discussed with them. What would they see as an adequate and well-conducted trial?

31:41 Jonathan, let me provide you some data and some color in addition to Dr. Kwong's comment. So the first point that they brought up was the neutropenia-related sequelae in terms of the fact that in the early part of the study, there was some early myelotoxicity. So just for your information, within the first 19 weeks of the trial, here we have the ORR, or the Response Rate First Rack, the death rates were actually very similar, roughly around 9% for IV practical taxone and 8% for the oral practical taxone in terms of mortality. So basically, I think that the two ways to look at it, the myotoxicity-related side effect due to neutropenia, and also the overall benefit for the patients.

32:33 I mean, in fact, the first 19 weeks in terms of mortality, there was not much difference, or in fact, I mean, a little bit higher for each of the respective tax law. Now to remind you about the mutual premium, in our presentation in San Antonio meetings, We already presented that the grade three and four neutropenia for Oropecatexel was 30%, and for Ivupacatexel was 28.2%, so a difference of 1.8%. So these are the information we want to share with you. Certainly, in the risk-benefit ratio analysis, we need to obviously look for every single risk involved. That's highly appropriate. At the same time, The other sorts of benefits related to reduced neuropathy and then a substantial or significant increase in the response rate and also the survival should also be considered, and we're going to bring these points for discussion with the FDA in terms of the overall assessment of the risk-benefit ratio.

33:42 Got it. Thanks for taking my questions. Thank you. Our next question comes from the line of Kenan McKay with RBC Capital Markets. Please proceed with your question. Hi, a couple questions here. Johnson, just sort of first and foremost, would love to understand how is it that you plan to maximize shareholder value from here? You know, it seems like the FDA's request for another randomized clinical trial could be prohibitively expensive. So just wondering, one, what other funding options there are to pursue continued or actual development beyond more debt? I would certainly think there would be value and potentially strategic interest in your generics or manufacturing business or other remaining criteria geographies. And then I have a subsequent question on the FDA feedback in this era.

34:44 Certainly, we believe in the data. We believe we have very good data with regard to the benefit and also the risk involved are all within our expectations because vitropenia is a mechanism-based side effect of any cytotoxic type of attack. Certainly, we will go ahead and discuss the FDA. We will be presenting the data and then try to seek their feedback. We believe that we are going to provide more data. Hopefully, they will consider that that is sufficient in terms of changing their view already. But if not then, I mean, they did not specify with regard to the nature of the study, nor did they use the word control study, actually, in their recommendation. So we would like to seek their feedback with regard to what type of study will be needed to set aside them as the sort of recommend by a former sort of question.

35:50 In terms of whether a pattern study of a smaller nature showing the same direction, but at the same time showing certain directions that are recommended by FDA will be able to provide data to their satisfaction, this remains to be discussed. Now, if it's a small study, we may be in a position to support it. Certainly, it is a big study. We are professionals. We will have to reconsider with regard to how big the study, the financial implications, the time involved, and also the competing nature of our other programs as well as the competitive landscape before we can make a firm decision. So I apologize for giving you a long answer, but there are many factors to consider, in particular, the response from FDA before we can have any clarity after our analysis with regard to how to push this program forward.

36:47 Sure. And maybe then, that's a segue to my second question. It seems like that FDA feedback in the CRL, it was certainly a huge surprise to me, given your prior interactions and even some of theirs, such as granting that shortened priority review. So maybe for you, Jonathan, as well as Rudolph, how do you reconcile your prior Apparently, positive reactions and communications with the FDA on this trial design. And, I mean, gosh, your 2018 press release literally titled, Affinex Receives Positive Feedback from FDA on Design of Phase III Clinical Trial for Raxal. And also, the FDA granting that prestigious priority review and lack of an advisory committee meeting or an ODAC with this CRL requesting, you know, a trial representative of U.S.

37:41 patient population and U.S. standard of care. It seems like somewhere very mixed messaging or crossed wires.

37:50 Thank you. Rudolph, do you want to address this question?

37:54 Absolutely. I think we clearly have discussed with the FDA about the study design and the fact that it's not conducted in the U.S. because of the comparative harm with the FDA and clearly received written documentation from them confirming that. one single study as we proposed is sufficient should the results be positive, and that the second consideration is really the benefit-risk as shown by the data. And certainly, when we submit the NDA package, all the information we are talking that they have seen, are included in the submission, so all those safety data, neutral opinion data that we present in San Antonio in the survival analysis were all in the submission package, and we waited for their standard 60 days to announce acceptance of the submission.

38:59 gave us the palliative review, so all those were very positive, and certainly along the way, I cannot explain, there are a lot of those, for example, the myelotoxicity, which is known, well documented, and we come up with a proposal that we can minimize that. And the central lab, they hung up this on a golden standard in the industry. We don't know what those hung up is, and to a certain extent that we also offer to say that even if you take into the worst-case scenario that there were re-reads, there were only a minimal number of re-reads, which were two, and one of them changed the result, and if you incorporate that result, change in there, it actually favor or actually more. So we don't know what the hang-up is.

39:51 We really are completely confused by this change. So we will clarify that with the agency going forward. I think I suspect reading the letter is purely my suspicion that they're focusing on the U.S. population in their letter that they perhaps are looking for some more U.S. data. That's purely my speculation at this time point. Rudolph, one follow-up on that. It seems like some of the concern around bias in the blinded reviewer introduction of bias there could be mitigated by just looking at some of the overall survival data, which obviously can't be biased.

40:43 Just wondering on FDA's perspective on that overall survival data, and then secondary to that, Just thinking about the U.S. population, to your point, obviously much more use of GCSF growth factors to prevent some of the neutropenia. If you were thinking about running a trial, whether single-arm or double-arm, In the U.S., again, building off the experience that you've gained from this trial, what kind of things could you add to the protocol to limit some of these adverse events like neutropenia that we saw and some of the even GI tox that we're seeing, at least in the first half of the prior phase three?

41:30 Yeah. This is very interesting. We have ongoing studies in the U.S. for example, the iSpy2, for example, the angiosarcoma program, which we are collecting more and more experience in the U.S. patient population, even as we speak. And certainly, with the U.S. way of practice, we haven't encountered a similar level of myelotoxicity in the early stage as seen in the study. So perhaps the U.S. population may give us a handle how the U.S.

42:16 clinician can handle this better. Now this is early stage, so I'll be cautious about it, but certainly you expect to hear more about those data as they become more mature. But certainly we certainly watch the safety signal, and certainly we are feeling good about the same dosing regimen being used in a much elderly population In the angiosarcoma patient population, they are in the 60s, 70s, 80s, and the 90s. And in the I-SPY2, where they're co-administered with multiple other drugs. So we certainly do not see such a worrying signal in those early data that we're seeing. So we'll continue to follow that up and propose that whether that can be part of the way that we can understand what they mean by collecting more information on the U.S. population.

43:11 Does that answer your question? It does. And one final question that segues off something you had brought up, and that's the angiosarcoma population. This is obviously an area of huge unmet need for a small indication and potentially could see a much more accelerated path to market, maybe even a faster path to market than in breast cancer now. Just wondering if you have approached the FDA on a path to market in that population or how you could potentially go about that.

43:52 We always obtain the open drug destination from the FDA, and we, We are very actively completing that study. I think we are either completed enrollment, about to complete enrollment, of the 43 patient single arm study. And as you have seen in some of our earlier reports, the results are extremely encouraging, with really good results. dramatic and convincing responses as evidenced by the pictures we put in San Antonio and previously in other medical conferences. And certainly, it's an area where there's no approved treatment. and a very rare disease, so that could be an interesting venue to see how the FDA would react to our data that could be collected and presented to them.

44:53 We intend to request a formal meeting with the FDA to discuss the path forward for this integration. Bear in mind, this is a rare disease, but also, where disease may be treated differently than other disease within the agency. So we certainly will be aggressively progressing the regulatory consultation of that test bed. Thank you. Thank you, Cameron. Thank you. Ladies and gentlemen, to allow for as many questions as possible, we ask that you keep to one question and one follow-up each. Our next question comes from the line of Robin Karnoskis with Truist Securities.

45:39 Please proceed with your question. Hi, guys. Thank you. I guess here are my two. Can we just explore the worst-case scenario and the best-case scenario? So under a worst-case scenario where you're forced to do another trial, do you have an estimate as to, you know, how long that would take you? Like, you're saying you're CASTOR 2023. If that is a possibility, would you still explore it if they actually ask for, like, a much more controlled study or a bigger study just because there is a patent expiration for this product? And then the second question is more on the best case scenario. So can you walk us through the timelines for when you're going to speak to the FDA next? I assume you have to get documentation together and some proposals together, so it might take some time. And then, you know, time to request a meeting, then have the meeting, and how you're going to convey to the street the outcome.

46:31 Like, for example, would you wait until after you have the minute? Just help us get some bookends and, like, you know, best case, worst case, and timelines. Thanks.

46:41 Thank you, Robin. I think with regard to the first question, based on the two major concerns from FDA in terms of the neutropenia-related secretaries, I think we do have data that we believe we can make a case with regard to the fact that this is a mechanism-based side effect that is manageable, and there's some concern whether a small study will be able to address the concern and how to design. Besides the study, will it take a lot? How long will it take and the resources required to handle the particular concern? Now, the concern with regard to the blinded independent central review, we already present information together with our CRO that the entire process was being done in a blinded and also well-controlled and all the processes were documented. As mentioned by Dr.

47:35 Kwan, the reconciliation process and the regret process that they have some concern on the unmeasured bias involved only two patients. And one did not have any change or curve related data in the process. And the other one, actually, if you actually take consideration into that, it actually make our data look even better. So therefore, I think there's some concern with the data process. Obviously, we'll try our best in terms of going back to present the independency of the data. We feel that, I mean, once we understand how independent the process is, that they may have a different opinion with regard to the integrity and the quality of our data.

48:20 So with regard to your question on the study, if it's a small study, then I'm just looking for direction. I'm quite sure that this can be sort of arranged, and obviously we'll try our best to provide data to FDA as soon as possible. The other aspects are already addressed, so therefore the review process by FDA may be expedited. Now with regard to timeline for our submission to FDA and then ask for a Type A meeting, obviously we need to submit a package before we have a timeline. Dr. Kwan's team is working very hard and we are trying to prepare the package as soon as possible. Hopefully within a couple of weeks and then followed by a request to FDA, and we sincerely hope that FDA will grant us the meeting as soon as possible.

49:08 But the usual timeline is that the meeting will be occurring within 30 days. So we are looking into a couple weeks together with the timeline that the FDA will grant us the meeting. And I think we will have some clarity very soon. And one follow-up, if I may. I mean, usually with, I think, data points like this, A lot of times people get refused to file because it's the data integrity question or the DICR question. Did you have any changes with the people you were interacting with between the people that you initially spoke with regarding approval of the trial in 2018, the acceptance of the filing in today? Are there any changes?

49:53 And any KOL experts, I'm sure you have FDA advisors who advise you on filings. What are they saying about We've seen this happen once before in the space, more recently, where there's been a surprise on the theater side. Maybe some color there would be really helpful for us.

50:15 Right. As far as I recall, when we submitted the protocol more than three years ago to the FDA, it was a nice upside surprise for us because we expect to have a conversation with FDA with regard to the protocol. And we sent a letter, I think in early January, that they sent us a letter saying that based on what we have submitted on the protocol, And if I remember correctly, the comment was that if we meet the primary endpoint and demonstrate the risk-benefit ratio, the setting design is adequate for FDA to consider approving the product. And it was a very simple two-sentences letter that we have received, followed by the standard information with regard to the other aspects of Phase I or other requirements to be followed.

51:09 So that was the basis of the letter that we received and the press release that we received based on the information available in the letter. Now, I mean, again, I mean, with that, then, I mean, would there be, then would there not be many names attached in that letter? And then, followed by a number of developments with regard to the pre-submission meeting followed by the subsequent discussion. Since Dr. Kwan is leading the effort. I would like Dr. Kwan to address a question with regard to whether there's change in personnel from the early stage to recently with regard to the viewing process. Dr. Kwan?

51:56 I think it would be fair to say we don't think there's any change in personnel from the submission. We had a pre-submission Type C meeting with the FDA to discuss the SAP and everything to the process along the way. I cannot remember the 2018 meeting where the group were essentially similar. That I cannot answer. Okay, thank you.

52:28 Thank you, Heather. Thank you. Our next question comes from mine of Kevin DeGieter with Oppenheimer. Please proceed with your question. Hey, guys, thanks for taking my questions. Rudolph, one of the areas of differentiation in our work was the neuropathy profile for the oral pacotaxel. Any comment or light you could share as to whether that was viewed by FDA as a material consideration in the benefit-risk profile for patients?

53:04 I think, Kevin, my interpretation would be when we make the submission that then when they accept it as a priority review, they would have seen and understand that probably is what drives it in neuropathy. And as you see in the St. Antonio 2020 report, I think we probably update the continuing thing, follow on, and show that the neuropathy is clearly differentiating. And I still have to see another approach in the Texin area where you can differentiate the neuropathy in such a way. despite the neutropenia profile and also in view of the advocacy benefits we have witnessed in the study.

54:10 So that's truly an intriguing differentiating factor which has been echoed by all the KOLs we have talked with. So your question is whether the FDA acknowledged it. I would assume they would have acknowledged it when they assigned the priority review, but certainly that has not been raised in the discussion along the way ever since. is something we believe we would raise with the FDA when one do a proper benefit-risk assessment. Perhaps that should provide more evidence, and we certainly intend to discuss with KOLs in the U.S. how that can be viewed from the clinician side.

54:58 So thank you for asking the question. Great. And my follow-up question, building on the comments from my colleagues that suggest that, at least in my view as well, that this seems to be largely a U.S. data question. Can you remind us with regard to regulatory strategy for jurisdictions outside the U.S.? And does that recognize it is not ideal to have the CRL, well, engage in regulators in other jurisdictions, but, you know, The modes of delivery of care for patients are different in different jurisdictions, and there would seem to be a strong risk-benefit analysis to take to other regulators in other jurisdictions as well.

55:45 Absolutely. Those will be what we are actively exploring. Within the company, we certainly were exploring the EMA and the MHRA. MHRA, by the way, is the UK that's recently established. leave the European Union following Brexit. So those are the venues that we would actively be pursuing. And certainly previously, our partners have interacted with the Australian and New Zealand health agency, and we'll continue to explore that. And also in the other Asia area, Taiwan, we had, our partner had an interaction before, and we are expecting our partner in China, Sanxie, to start negotiating with the China FDA, where we have an active IMD on Orexo in China.

56:40 So those are the venues that we were pursuing, and we certainly will continue present our case of the FDA response to the health authority to see whether there's different interpretation. They might be profile of the drug, is actually may potentially be ideal for countries that have a healthcare system where the use of an oral taxin may add significant additional benefit apart from the clinical benefit to the healthcare system. So we will actively explore those options.

57:30 Thank you. Our next question comes from the line. Aviel Jantz with Laid Law & Company. Please proceed with your question. Good morning, and thanks for taking the questions. Excuse me. My first question is that given the Abraxin, although that's about more than a decade ago, was approved mainly based on the data from the Russia and Ukraine, which account for more than two-thirds of the population studied. Is that an issue? Do you think that the FDA wants to have slightly more U.S. population and that that will be the sort of data set they will consider versus they need something completely in the U.S.

58:21 for a much larger study?

58:26 I will clearly discuss with them. I think the way they word it as I read it is representative of US population, not conducted in the U.S. Now, what do they mean by that is certainly a topic for discussion, and certainly if the representation is acceptable and that it is not an entirely U.S.-based study that allows more flexibility in operation, but it all really boils down in terms of the proposal that may be acceptable to them, what would they like? probably answer that with better clarity once we had our meeting with the FDA.

59:16 Okay, that's very helpful. And one more follow-up question here is that we certainly recognize that blinded review is a gold standard, and it's not that clear why FDA has suggested that there may be bias introduced. So in your future meetings with the agency, would you be able to add more specifics what they have seen? the so-called potential bios being introduced so you will have a better sense of what they really mean.

59:50 Absolutely, and that's an interesting dialogue that I would anticipate because in the old days, maybe even the vaccine study, when the FDA is not certain, they probably would look at the radiograph themselves, right? Or refer to a central independent lab when this investigation is initiated. In this case, we already used the state of the art. Bear in mind the central read process is very straight. we used two independent readers that are trained in receipts. They are specially trained. Bear in mind, the investigators are not always fully up to date and trained in receipts. It's clinical practice versus research. Whereas in the central lab, they were fully trained and they with the scans following different procedures that are completely blinded way, and their reading has to correlate, and if they don't correlate, then a third independent reader, completely blind, will adjudicate, so all those processes are really state of the art. So I have struggled to find out how we can move away from those unmeasurable bias because in the old days, the FDA probably when they have time, obviously in this case they didn't have time, would have taken the scans and analyzed themselves and probably collaborate what the blind individuals

1:01:22 would have done. And I don't know how one can, certainly it's a question we will explore with the FDA, whether they want to do that task or they want to assign an additional central lab to look at the scans. Those topics will be something that we'll raise with them. Okay, great. And thanks a lot, and we'll move forward. Thank you. Thank you. Thank you. Our next question comes from Matt Kaplan with Lattenberg-Solomon. Please proceed with your question.

1:01:51 Hi, this is Raymond, InfoMath. Just a quick question, and then we'll follow. I was wondering if you could provide any additional color on the dose optimization language that the agency provided?

1:02:06 We don't know. No, certainly not. I think we did discuss, I think, We did discuss early stage when we talked with the agency about the labeling language for those dosing, then there was a question how those adjustments should be made in patients with hepatic impairment. And we did propose to use it as in the protocol. That's what we did. And so that was the only discussion we had with them. And so I presume this will be a follow-on of what kind of dose optimization would be considered best for those higher risk groups. Just reading the language. Those are the questions that we want to clarify with them.

1:02:51 Okay, cool. And just may I follow this?

1:02:54 Is there perhaps an impact on just the pipeline in general due to the language from the FDA, perhaps? You can provide some additional call on that.

1:03:06 Let me answer the question. The two questions that were asked, one was mainly on architecture-specific adverse events or side effects, and the second one was a question on making sure that the private independent central review was appropriate according to their assessment. And I think none of them are really tied to the technology platform that we are working on right now. So therefore, based on this assessment, there should not be impact with regard to the platform and how we're going to pursue other programs. Certainly, I mean, when there's something that ties into a platform, I mean, the image is there and we obviously will have to work through and ensure that we provide sufficient data to make sure that the confidence is restored for both investors, for the regulatory agencies, for patients, and for clinicians.

1:04:05 Okay. Thank you. Thank you. Ladies and gentlemen, this concludes our question-and-answer session. I'll turn the floor back to Dr. Lau for any final comments.

1:04:18 Thank you. During the last three months, we have had the approval and launch of QSERI and received a complete response letter from the FDA on Oropecataxel. Our team will continue working towards a path forward with FDA to address the concerns on the OPEC tax law and the package. At the same time, we are working to identify and undertake the appropriate internal organizational adjustments accordingly, and we communicate information regarding disinformation when more information is available. Thank you for your time in joining us in call this morning. This concludes today's conference. You may disconnect your lines at this time.

1:05:03 Thank you for your participation.

Follow Athenex Inc into a list and get an email when it puts out news.

Companies on this call

Speakers

Steve Rubis

Senior Director of Investor Relations

Dr. Johnson Lau

Chief Executive Officer

Dr. Rudolph Kwan

Chief Medical Officer

Mr. Jeff Yorden

Chief Operating Officer

Mr. Randall See

Chief Financial Officer

More from Athenex Inc